The role of asymmetric and symmetric dimethylarginines in renal disease

Nature Reviews Nephrology

Volumn 7, Issue 5, 2011, Pages 275-285

  Schwedhelm, Edzard ^a   Böger, Rainer H ^a  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

6 N,N' DIMETHYLARGININE; AMINO ACID TRANSPORTER; ANGIOTENSIN II; ARGININE; BIOLOGICAL MARKER; CHROMIUM 51; CITRULLINE; CYANOCOBALAMIN; DIMETHYLARGININASE; HOMOCYSTEINE; HOMOCYSTEINE METHYLTRANSFERASE; MESSENGER RNA; METHIONINE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PROTEIN ARGININE METHYLTRANSFERASE; PYRIDOXINE; S ADENOSYLMETHIONINE;

AMINO ACID BLOOD LEVEL; AMINO ACID TRANSPORT; ATHEROGENESIS; ATHEROSCLEROSIS; BIOLOGICAL ACTIVITY; BIOSYNTHESIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CELL TRANSPORT; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; DISEASE COURSE; ELIMINATION REACTION; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVITY; ENZYME DEGRADATION; ENZYME INHIBITION; HEMODIALYSIS; HUMAN; HYPERHOMOCYSTEINEMIA; HYPERTENSION; KIDNEY DYSFUNCTION; KIDNEY PARENCHYMA; MORTALITY; NONHUMAN; PREDICTIVE VALUE; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; VASOCONSTRICTION;

ARGININE; HUMANS; KIDNEY; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

EID: 79955623424     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2011.31     Document Type: Review

References (124)

1. Kakimoto, Y. & Akazawa S. Isolation and identification of NG,NG- and NG,N'G-dimethylarginine, Nå-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-delta-hydroxylysine from human urine. J. Biol. Chem. 245, 5751-5758 (1970).
2. Paik, W. K. & Kim, S. Protein methylation: chemical, enzymological, and biological significance. Adv. Enzymol. Relat. Areas Mol. Biol. 42, 227-286 (1975).
3. Vallance, P., Leone, A., Calver, A., Collier, J. & Moncada, S. Accumulation of an endogenous inhibitor of NO synthesis in chronic renal failure. Lancet 339, 572-575 (1992).
4. Kakimoto, Y. Methylation of arginine and lysine residues of cerebral proteins. Biochim. Biophys. Acta 243, 31-37 (1971).
5. Bedford, M. T. & Clarke, S. G. Protein arginine methylation in mammals: who, what, and why. Mol. Cell 33, 1-13 (2009).
6. Böger, R. H. et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation 95, 2068-2074 (1997). (Pubitemid 27184275)
7. Teerlink, T. et al. HPLC analysis of ADMA and other methylated l-arginine analogs in biological fluids. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851, 21-29 (2007). (Pubitemid 46720132)
8. Marra, M. et al. High-performance liquid chromatographic assay of asymmetric dimethylarginine, symmetric dimethylarginine, and arginine in human plasma by derivatization with naphthalene-2,3-dicarboxaldehyde. Anal. Biochem. 318, 13-17 (2003). (Pubitemid 36627477)
9. Blackwell, S., O'Reilly, D. S. & Talwar, D. K. HPLC analysis of asymmetric dimethylarginine (ADMA) and related arginine metabolites in human plasma using a novel non-endogenous internal standard. Clin. Chim. Acta 401, 14-19 (2009).
10. Blackwell, S., O'Reilly, D. S. & Talwar, D. Biological variation of asymmetric dimethylarginine and related arginine metabolites and analytical performance goals for their measurement in human plasma. Eur. J. Clin. Invest. 37, 364-371 (2007). (Pubitemid 46653140)
11. Schwedhelm, E. Quantification of ADMA: analytical approaches. Vasc. Med. 10 (Suppl. 1), S89-S95 (2005). (Pubitemid 43137272)
12. Martens-Lobenhoffer, J. & Bode-Böger, S. M. Chromatographic-mass spectrometric methods for the quantification of l-arginine and its methylated metabolites in biological fluids. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851, 30-41 (2007). (Pubitemid 46720133)
13. Tsikas, D. A critical review and discussion of analytical methods in the l-arginine/nitric oxide area of basic and clinical research. Anal. Biochem. 379, 139-163 (2008).
14. Schwedhelm, E. et al. High-throughput liquid chromatographic-tandem mass spectrometric determination of arginine and dimethylated arginine derivatives in human and mouse plasma. J. Chromatogr. B Analyt. Technol. Biomed. Life Sci. 851, 211-219 (2007). (Pubitemid 46720141)
15. Schulze, F. et al. Determination of asymmetric dimethylarginine (ADMA) using a novel ELISA assay. Clin. Chem. Lab. Med. 42, 1377-1383 (2004). (Pubitemid 40057825)
16. Schulze, F. et al. Determination of a reference value for NG,NG-dimethyl-l-arginine in 500 subjects. Eur. J. Clin. Invest. 35, 622-626 (2005). (Pubitemid 41406726)
17. Sydow, K. et al. Distribution of asymmetric dimethylarginine among 980 healthy, older adults of different ethnicities. Clin. Chem. 56, 111-120 (2010).
18. Rawal, N. et al. Structural specificity of substrate for S-adenosylmethionine: protein arginine N-methyltransferases. Biochim. Biophys. Acta 1248, 11-18 (1995).
19. Gary, J. D. & Clarke, S. RNA and protein interactions modulated by protein arginine methylation. Prog. Nucleic Acid Res. Mol. Biol. 61, 65-131 (1998).
20. Nicholson, T. B., Chen, T. & Richard, S. The physiological and pathophysiological role of PRMT1-mediated protein arginine methylation. Pharmacol. Res. 60, 466-474 (2009).
21. Ogawa, T., Kimoto, M. & Sasaoka, K. Occurrence of a new enzyme catalysing the direct conversion of NG,NG-dimethyl-l-arginine to l-citrulline in rats. Biochem. Biophys. Res. Commun. 148, 671-677 (1987).
22. Achan, V. et al. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler. Thromb. Vasc. Biol. 23, 1455-1459 (2003). (Pubitemid 36994536)
23. Leiper, J. M. et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem. J. 343, 209-214 (1999). (Pubitemid 29473897)
24. Pope, A. J., Karuppiah, K. & Cardounel, A. J. Role of the PRMT-DDAH-ADMA axis in the regulation of endothelial nitric oxide production. Pharmacol. Res. 60, 461-465 (2009).
25. Sanchez, S. E. et al. A methyl transferase links the circadian clock to the regulation of alternative splicing. Nature 468, 112-116 (2010).
26. Hsu, J. M. et al. Crosstalk between Arg 1175 methylation and Tyr 1173 phosphorylation negatively modulates EGFR-mediated ERK activation. Nat. Cell. Biol. 13, 174-181 (2011).
27. Kielstein, J. T., Salpeter, S. R., Bode-Boeger, S. M., Cooke, J. P. & Fliser, D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol. Dial. Transplant. 21, 2446-2451 (2006). (Pubitemid 44644516)
28. Kielstein, J. T. et al. Low dialysance of asymmetric dimethylarginine (ADMA)-in vivo and in vitro evidence of significant protein binding. Clin. Nephrol. 62, 295-300 (2004). (Pubitemid 39386806)
29. Böger, R. H. et al. LDL cholesterol upregulates synthesis of asymmetric dimethylarginine (ADMA) in human endothelial cells: involvement of S-adenosylmethionine-dependent methyltransferases. Circ. Res. 87, 99-105 (2000). (Pubitemid 30616904)
30. Böger, R. H., Bode-Böger, S. M., Sydow, K., Heistad, D. D. & Lentz, S. R. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in monkeys with hyperhomocyst(e)inemia. Arterioscler. Thromb. Vasc. Biol. 20, 1557-1564 (2000). (Pubitemid 30353888)
31. Böger, R. H., Lentz, S. R., Bode-Böger, S. M., Knapp, H. R. & Haynes, W. G. Elevation of asymmetrical dimethylarginine may mediate endothelial dysfunction during experimental hyperhomocyst(e)inaemia in humans. Clin. Sci. (Lond.) 100, 161-167 (2001). (Pubitemid 32165360)
32. Sydow, K. et al. Endothelial dysfunction in patients with peripheral arterial disease and chronic hyperhomocysteinemia: potential role of ADMA. Vasc. Med. 9, 93-101 (2004). (Pubitemid 39406423)
33. Doshi, S. N. et al. Investigation of the relationship between S-adenosylmethionine, S-adenosylhomocysteine, asymmetric dimethylarginine and endothelial function in healthy human subjects. Metabolism 54, 351-360 (2005).
34. Mariotti, F. et al. Medium-term methionine supplementation increases plasma homocysteine but not ADMA and improves blood pressure control in rats fed a diet rich in protein and adequate in folate and choline. Eur. J. Nutr. 45, 383-390 (2006). (Pubitemid 44630733)
35. Antoniades, C. et al. Asymmetrical dimethylarginine regulates endothelial function in methionine-induced but not in chronic homocystinemia in humans: effect of oxidative stress and proinflammatory cytokines. Am. J. Clin. Nutr. 84, 781-788 (2006). (Pubitemid 44717510)
36. Sydow, K. et al. ADMA and oxidative stress are responsible for endothelial dysfunction in hyperhomocyst(e)inemia: effects of l-arginine and B vitamins. Cardiovasc. Res. 57, 244-252 (2003). (Pubitemid 36009457)
37. Spoelstra-de Man, A. M. et al. No effect of B vitamins on ADMA levels in patients at increased cardiovascular risk. Clin. Endocrinol. (Oxf.) 64, 495-501 (2006).
38. Schmitt, B. et al. Effects of combined supplementation with B vitamins and antioxidants on plasma levels of asymmetric dimethylarginine (ADMA) in subjects with elevated risk for cardiovascular disease. Atherosclerosis 193, 168-176 (2007). (Pubitemid 46779119)
39. Böger, R. H. et al. ADMA: a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation 98, 1842-1847 (1998). (Pubitemid 28509278)
40. Böger, R. H. et al. Dietary l-arginine slows the progression of atherosclerosis in cholesterol-fed rabbits-comparison with lovastatin. Circulation 96, 1282-1290 (1997). (Pubitemid 27344234)
41. Cardounel, A. J. et al. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J. Biol. Chem. 282, 879-887 (2007). (Pubitemid 47076535)
42. Tsikas, D., Böger, R. H., Sandmann, J., Bode-Böger, S. M. & Frölich, J. C. Hypothesis: Endogenous nitric oxide synthase inhibitors are responsible for the l-arginine paradox. FEBS Lett. 478, 1-3 (2000). (Pubitemid 30462247)
43. Garvey, E. P. et al. Purification and characterization of the constitutive nitric oxide synthase from human placenta. Arch. Biochem. Biophys. 311, 235-241 (1994).
44. Closs, E. I., Simon, A., Vékony, N. & Rotmann, A. Plasma membrane transporters for arginine. J. Nutr. 134 (Suppl.), 2752S-2759S (2004). (Pubitemid 39315216)
45. Vallance, P., Leone, A., Calver, A., Collier, J. & Moncada, S. Endogenous dimethylarginine as an inhibitor of nitric oxide synthesis. J. Cardiovasc. Pharmacol. 20 (Suppl. 12), S60-S62 (1992). (Pubitemid 23014109)
46. Dayoub, H. et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation 108, 3042-3047 (2003). (Pubitemid 37553576)
47. Dayoub, H. et al. Overexpression of dimethylarginine dimethylaminohydrolase inhibits asymmetric dimethylarginine-induced endothelial dysfunction in the cerebral circulation. Stroke 39, 180-184 (2008).
48. Jacobi, J. et al. Role of asymmetric dimethylarginine for angiotensin II-induced target organ damage in mice. Am. J. Physiol. Heart Circ. Physiol. 294, H1058-H1066 (2008). (Pubitemid 351253320)
49. Jacobi, J. et al. Dimethylarginine dimethylaminohydrolaseoverexpression suppresses atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am. J. Pathol. 176, 2559-2570 (2010).
50. Leypoldt, F. et al. Dimethylarginine dimethylaminohydrolase-1 transgenic mice are not protected from ischemic stroke. PLoS One 4, e7337 (2009).
51. Schwedhelm, E. et al. Extensive characterization of the human DDAH1 transgenic mice. Pharmacol. Res. 60, 494-502 (2009).
52. Hasegawa, K. et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginine dimethylaminohydrolase 2. Circ. Res. 101, e2-e10 (2007). (Pubitemid 47196589)
53. Wang, D. et al. Isoform-specific regulation by NG,NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ. Res. 101, 627-635 (2007). (Pubitemid 351325880)
54. Leiper, J. et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat. Med. 13, 198-203 (2007).
55. Hu, X. et al. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation 120, 2222-2229 (2009).
56. Akbar, F. et al. Haplotypic association of DDAH1 with susceptibility to pre-eclampsia. Mol. Hum. Reprod. 11, 73-77 (2005). (Pubitemid 40331005)
57. Maas, R. et al. Polymorphisms in the promoter region of the dimethylarginine dimethylaminohydrolase 2 gene are associated with prevalence of hypertension. Pharmacol. Res. 60, 488-493 (2009).
58. Caplin, B. et al. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. Kidney Int. 77, 459-467 (2010).
59. Kielstein, J. T. et al. Marked increase of asymmetric dimethylarginine in patients with incipient primary chronic renal disease. J. Am. Soc. Nephrol. 13, 170-176 (2002). (Pubitemid 34042024)
60. Uchida, H. A. et al. Steroid pulse therapy impaired endothelial function while increasing plasma high molecule adiponectin concentration in patients with IgA nephropathy. Nephrol. Dial. Transplant. 21, 3475-3480 (2006). (Pubitemid 44817097)
61. Nijveldt, R. J. et al. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol. Dial. Transplant. 17, 1999-2002 (2002). (Pubitemid 35277101)
62. Sibal, L. et al. A study of endothelial function and circulating asymmetrical dimethylarginine levels in people with type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc. Diabetol. 8, 27 (2009).
63. Anderssohn, M., Schwedhelm, E., Lüneburg, N., Vasan, R. S. & Böger, R. H. Asymmetric dimethylarginine as a mediator of vascular dysfunction and a marker of cardiovascular disease and mortality: an intriguing interaction with diabetes mellitus. Diab. Vasc. Dis. Res. 7, 105-118 (2010).
64. Kimoto, M., Whitley, G. S., Tsuji, H. & Ogawa, T. Detection of NG,NG-dimethylarginine dimethylaminohydrolase in human tissues using a monoclonal antibody. J. Biochem. 117, 237-238 (1995).
65. Tojo, A. et al. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 52, 1593-1601 (1997). (Pubitemid 28032063)
66. Tran, C. T., Fox, M. F., Vallance, P. & Leiper, J. M. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics 68, 101-105 (2000).
67. Carello, K. A., Whitesall, S. E., Lloyd, M. C., Billecke, S. S. & D'Alecy, L. G. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am. J. Physiol. Heart Circ. Physiol. 290, H209-H216 (2006).
68. Tatematsu, S. et al. Role of nitric oxide-producing and -degrading pathways in coronary endothelial dysfunction in chronic kidney disease. J. Am. Soc. Nephrol. 18, 741-749 (2007). (Pubitemid 46434491)
69. Kalousová, M. et al. No benefit of hemodiafiltration over hemodialysis in lowering elevated levels of asymmetric dimethylarginine in ESRD patients. Blood Purif. 24, 439-444 (2006). (Pubitemid 46030085)
70. Grooteman, M. P., Wauters, I. M., Teerlink, T., Twisk, J. W. & Nubé, M. J. Plasma dimethylarginine levels in chronic hemodialysis patients are independent of the type of dialyzer applied. Blood Purif. 25, 281-289 (2007). (Pubitemid 47074644)
71. Zoccali, C. et al. Plasma concentration of asymmetrical dimethylarginine and mortality in patients with end-stage renal disease: a prospective study. Lancet 358, 2113-2117 (2001). (Pubitemid 34094901)
72. Valkonen, V. P. et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet 358, 2127-2128 (2001).
73. Zoccali, C. et al. Asymmetric dimethylarginine (ADMA), C-reactive protein, and carotid intima media-thickness in end-stage renal disease. J. Am. Soc. Nephrol. 13, 490-496 (2002). (Pubitemid 34106292)
74. Zoccali, C. et al. Left ventricular hypertrophy, cardiac remodelling and asymmetric dimethylarginine (ADMA) in hemodialysis patients. Kidney Int. 62, 339-345 (2002). (Pubitemid 34754080)
75. Busch, M., Fleck, C., Wolf, G. & Stein, G. Asymmetrical (ADMA) and symmetrical dimethylarginine (SDMA) as potential risk factors for cardiovascular and renal outcome in chronic kidney disease-possible candidates for paradoxical epidemiology? Amino Acids 30, 225-232 (2006). (Pubitemid 43724049)
76. Ravani, P. et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J. Am. Soc. Nephrol. 16, 2449-2455 (2005). (Pubitemid 41725063)
77. Fliser, D. et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J. Am. Soc. Nephrol. 16, 2456-2461 (2005). (Pubitemid 41725064)
78. Böger, R. H. et al. Asymmetric dimethylarginine as independent risk marker for mortality in ambulatory patients with peripheral arterial disease. J. Intern. Med. 269, 349-361 (2011).
79. Schulze, F. et al. Symmetric dimethylarginine predicts all-cause mortality following ischemic stroke. Atherosclerosis 208, 518-523 (2010).
80. Böger, R. H. et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation 119, 1592-1600 (2009).
81. Schwarz, P., Diem, R., Dun, N. J. & Förstermann, U. Endogenous and exogenous nitric oxide inhibits norepinephrine release from rat sympathetic nerves. Circ. Res. 77, 841-848 (1995).
82. Costa, F., Christensen, N. J., Farley, G. & Biaagioni, I. NO modulates norepinephrine release in human skeletal muscle: implications for neural preconditioning. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R1494-R1498 (2001).
83. Owlya, R. et al. Cardiovascular and symathetic effects of nitric oxide inhibition at rest and during static exercise in humans. Circulation 96, 3897-3903 (1997).
84. Hijmering, M. L. et al. Sympathetic activation markedly reduces endothelium-dependent, flow-mediated vasodilation. J. Am. Coll. Cardiol. 39, 683-688 (2002). (Pubitemid 34158166)
85. Mallamaci, F. et al. Analysis of the relationship between norepinephrine and asymmetric dimethylarginine in patients with end-stage renal disease. J. Am. Soc. Nephrol. 15, 435-441 (2004). (Pubitemid 38140785)
86. Nijveldt, R. J. et al. Asymmetrical dimethylarginine (ADMA) in critically ill patients: high plasma ADMA concentration is an independent risk factor of ICU mortality. Clin. Nutr. 22, 23-30 (2003). (Pubitemid 36193177)
87. Zeller, M. et al. Impact of asymmetric dimethylarginine on mortality after acute myocardial infarction. Arterioscler. Thromb. Vasc. Biol. 28, 954-960 (2008). (Pubitemid 351544113)
88. Lu, T. M., Ding, Y. A., Lin, S. J., Lee, W. S. & Tai, H. C. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur. Heart J. 24, 1912-1919 (2003).
89. Schnabel, R. et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ. Res. 97, e53-e59 (2005).
90. Meinitzer, A. et al. Asymmetrical dimethylarginine independently predicts total and cardiovascular mortality in individuals with angiographic coronary artery disease (the Ludwigshafen Risk and Cardiovascular Health study). Clin. Chem. 53, 273-283 (2007). (Pubitemid 46338272)
91. Dückelmann, C. et al. Asymmetric dimethylarginine enhances cardiovascular risk prediction in patients with chronic heart failure. Arterioscler. Thromb. Vasc. Biol. 27, 2037-2042 (2007). (Pubitemid 47312315)
92. Mittermayer, F. et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler. Thromb. Vasc. Biol. 26, 2536-2540 (2006). (Pubitemid 44607477)
93. Krzyzanowska, K., Mittermayer, F., Wolzt, M. & Schernthaner, G. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care 30, 1834-1839 (2007). (Pubitemid 47036360)
94. Böger, R. H. et al. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J. Am. Coll. Cardiol. 36, 2287-2295 (2000).
95. Schepers, E., Glorieux, G., Dhondt, A., Leybaert, L. & Vanholder, R. Role of symmetric dimethylarginine in vascular damage by increasing ROS via store-operated calcium influx in monocytes. Nephrol. Dial. Transplant. 24, 1429-1435 (2009).
96. Stühlinger, M. C. et al. Asymmetric dimethyl l-arginine (ADMA) is a critical regulator of myocardial reperfusion injury. Cardiovasc. Res. 75, 417-425 (2007). (Pubitemid 46961932)
97. Böger, R. H. Asymmetric dimethylarginine (ADMA): a novel risk marker in cardiovascular medicine and beyond. Ann. Med. 38, 126-136 (2006).
98. Maas, R. et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin. Chem. 53, 693-701 (2007). (Pubitemid 46580240)
99. Leong, T. et al. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler. Thromb. Vasc. Biol. 28, 961-967 (2008). (Pubitemid 351544114)
100. Kakimoto, Y. & Akazawa, S. Isolation and identification of NG,NG-and NG,N'G-dimethyl-arginine, Nå-mono-, di-, and trimethyllysine, and glucosylgalactosyl- and galactosyl-ä-hydroxylysine from human urine. J. Biol. Chem. 245, 5751-5758 (1970).
101. Closs, E. I., Basha, F. Z., Habermeier, A. & Förstermann, U. Interference of l-arginine analogues with l-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1, 65-73 (1997). (Pubitemid 28078129)
102. Bode-Böger, S. M. et al. Symmetrical dimethylarginine: a new combined parameter for renal function and extent of coronary artery disease. J. Am. Soc. Nephrol. 17, 1128-1134 (2006).
103. Fleck, C., Schweitzer, F., Karge, E., Busch, M. & Stein, G. Serum concentrations of asymmetric (ADMA) and symmetric (SDMA) dimethylarginine in patients with chronic kidney diseases. Clin. Chim. Acta 336, 1-12 (2003). (Pubitemid 37336493)
104. Yilmaz, M. I. et al. ADMA levels correlate with proteinuria, secondary amyloidosis, and endothelial dysfunction. J. Am. Soc. Nephrol. 19, 388-395 (2008). (Pubitemid 351240660)
105. Oner-Iyidogan, Y. et al. Dimethylarginines and inflammation markers in patients with chronic kidney disease undergoing dialysis. Clin. Exp. Med. 9, 235-241 (2009).
106. Caglar, K. et al. ADMA, proteinuria, and insulin resistance in non-diabetic stage I chronic kidney disease. Kidney Int. 70, 781-787 (2006). (Pubitemid 44215355)
107. Brooks, E. R. et al. Methylated arginine derivatives in children and adolescents with chronic kidney disease. Pediatr. Nephrol. 24, 129-134 (2009).
108. Aucella, F. et al. Methylarginines and mortality in patients with end-stage renal disease: a prospective cohort study. Atherosclerosis 207, 541-545 (2009).
109. Billecke, S. S. Blood content of asymmetric dimethylarginine: new insights into its dysregulation in renal disease. Nephrol. Dial. Transplant. 24, 489-496 (2009).
110. Csiky, B. et al. Response of asymmetric dimethylarginine to hemodialysis-associated hypotension in end-stage renal disease patients. Nephron Clin. Pract. 108, c127-c134 (2008). (Pubitemid 351346936)
111. Aslam, S., Santha, T., Leone, A. & Wilcox, C. Effects of amlodipine and valsartan on oxidative stress and plasma methylarginines in end-stage renal disease patients on hemodialysis. Kidney Int. 70, 2109-2115 (2006). (Pubitemid 44871373)
112. Goonasekera, C. D. et al. Nitric oxide synthase inhibitors and hypertension in children and adolescents. J. Hypertens. 15, 901-909 (1997). (Pubitemid 27344855)
113. Marescau, B. et al. Guanidino compounds in serum and urine of nondialyzed patients with chronic renal insufficiency. Metabolism 46, 1024-1031 (1997). (Pubitemid 27371819)
114. Al Banchaabouchi, M. et al. NG,NG-dimethylarginine and NG,NG-dimethylarginine in renal insufficiency. Pflugers Arch. 439, 524-531 (2000).
115. Ellis, J. et al. Levels of dimethylarginines and cytokines in mild and severe preeclampsia. Acta Obstet. Gynecol. Scand. 80, 602-608 (2001). (Pubitemid 32626055)
116. Tarnow, L., Hovind, P., Teerlink, T., Stehouwer, C. D. & Parving, H. H. Elevated plasma asymmetric dimethylarginine as a marker of cardiovascular morbidity in early diabetic nephropathy in type 1 diabetes. Diabetes Care 27, 765-769 (2004). (Pubitemid 38280547)
117. Nanayakkara, P. W. et al. Plasma asymmetric dimethylarginine (ADMA) concentration is independently associated with carotid intima-media thickness and plasma soluble vascular cell adhesion molecule-1 (sVCAM-1) concentration in patients with mild-to-moderate renal failure. Kidney Int. 68, 2230-2236 (2005). (Pubitemid 43117798)
118. Wang, J. et al. Relations between plasma asymmetric dimethylarginine (ADMA) and risk factors for coronary disease. Atherosclerosis 184, 383-388 (2006). (Pubitemid 43049724)
119. Wanby, P. et al. Asymmetric dimethylarginine (ADMA) as a risk marker for stroke and TIA in a Swedish population. Atherosclerosis 185, 271-277 (2006).
120. Siroen, M. P. et al. No compensatory upregulation of placental dimethylarginine dimethylaminohydrolase activity in preeclampsia. Gynecol. Obstet. Invest. 62, 7-13 (2006). (Pubitemid 43999337)
121. Lluch, P. et al. Accumulation of symmetric dimethylarginine in hepatorenal syndrome. Exp. Biol. Med. 231, 70-75 (2006). (Pubitemid 43063978)
122. Kumagai, H. et al. Association of homocysteine and asymmetric dimethylarginine with atherosclerosis and cardiovascular events in maintenance hemodialysis patients. Am. J. Kidney. Dis. 48, 797-805 (2006). (Pubitemid 44740047)
123. Young, J. M. et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin. J. Am. Soc. Nephrol. 4, 1115-1120 (2009).
124. Abedini, S. et al. Asymmetrical dimethylarginine is associated with renal and cardiovascular outcomes and all-cause mortalilty in renal transplant recipients. Kidney Int. 77, 44-50 (2010).